Mora J et al.

Summary - Irinotecan/cisplatin (I/C) chemotherapy resulted in good disease control and clinical improvement in children with low-grade glioma (LGG), and toxicity was mild

Methods
Cisplatin (30 mg/m2) and irinotecan (50–65 mg/m2) were administered weekly for a total maximum of 16 doses.

Results
31 children with LGG were studied.  
The overall objective response and disease control rates to I/C treatment were 6.5% and 93.5%, respectively.
Disease control persisted for a median of 65 months.
Myelosuppression was the most common untoward effect.
The 5-year event-free survival was 54% and the 5-year OS was 80%.